Ocugen Inc. (OCGN)
OCGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price · October 14, 2026
$0.8854
-6.52% on the day
Market cap
$300.2M
Small cap
Revenue · 2025
$4.4M
+8.8% on 2024
Net income · 2025
-$68.0M
-1540.9% net margin
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC XBRL frames, calendar 2025.
Profile
| Field | Value |
|---|---|
| Ticker | OCGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001372299 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.4M |
| Net income | -$68.0M |
| Operating income | -$62.9M |
| Net margin | -1540.9% |
| Operating margin | -1425.7% |
| Revenue growth | +8.8% |
| Cash | $18.6M |
| Total assets | $43.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 68.0× |
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-21 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-08-06 |
| Latest current report | 8-K | 2026-10-06 |
| Latest proxy | DEFA14A | 2026-08-14 |
Source: SEC EDGAR submissions feed, 888 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -19.4% |
| 1 month | -18.9% |
| 3 months | -41.1% |
| Year to date | -40.3% |
| 1 year | -49.6% |
| From 52-week high | -67.5% |
Source: Yahoo Finance daily closes, last bar 2026-10-14. Computed by Sophia Capital from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| IRLA | IRulya Therapeutics Inc. | $27.87 | -13.98% | $302.2M |
| ARTV | Artiva Biotherapeutics Inc. | $6.29 | -7.09% | $307.5M |
| AGEN | Agenus Inc. | $6.95 | -6.46% | $313.9M |
| CABA | Cabaletta Bio Inc. | $1.69 | -5.59% | $286.5M |
| SRZN | Surrozen Inc. | $23.51 | -5.05% | $276.3M |
| CCCC | C4 Therapeutics Inc. | $2.78 | -9.15% | $342.0M |
| XFOR | X4 Pharmaceuticals Inc. | $2.60 | -7.80% | $257.8M |
| PALI | Palisade Bio Inc. | $1.47 | -7.86% | $255.3M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier